Effects of beta-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, In Sook | - |
dc.contributor.author | Kim, Yun | - |
dc.contributor.author | Kwak, Tae Hwan | - |
dc.contributor.author | Yoo, Hye Hyun | - |
dc.date.accessioned | 2021-06-23T02:43:59Z | - |
dc.date.available | 2021-06-23T02:43:59Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2013-09 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/27146 | - |
dc.description.abstract | This study aimed to assess the potential inhibitory effects of beta-lapachone, a new anticancer candidate, on the activities of the cytochrome P450 (CYP450) enzymes in vitro. Different concentrations of beta-lapachone were incubated with human liver microsomes in the presence of CYP isozyme-specific substrates and NADPH, and the formation of the marker metabolites was measured using liquid chromatography-tandem mass spectrometry. In addition, time-dependent inhibition was examined to characterize the mode of the inhibition. beta-Lapachone showed concentration-dependent inhibitory effects on all CYP isozymes tested (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYPC19, CYP2D6, and CYP3A4), and its half-maximal inhibitory concentration (IC50) values ranged from 2.6 to 9.7 mu M. However, beta-lapachone did not appear to modulate CYP450 activities as a mechanism-based inactivator. These results suggest that pharmacological drug-drug interactions might occur between beta-lapachone and drugs co-administered with it, which are extensively metabolized by CYP450 enzymes, and thus, careful observation is required in clinical pharmacokinetic studies. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Springer Verlag | - |
dc.title | Effects of beta-lapachone, a new anticancer candidate, on cytochrome P450-mediated drug metabolism | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoo, Hye Hyun | - |
dc.identifier.doi | 10.1007/s00280-013-2230-x | - |
dc.identifier.scopusid | 2-s2.0-84883487909 | - |
dc.identifier.wosid | 000323653600021 | - |
dc.identifier.bibliographicCitation | Cancer Chemotherapy and Pharmacology, v.72, no.3, pp.699 - 702 | - |
dc.relation.isPartOf | Cancer Chemotherapy and Pharmacology | - |
dc.citation.title | Cancer Chemotherapy and Pharmacology | - |
dc.citation.volume | 72 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 699 | - |
dc.citation.endPage | 702 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | PROSTATE-CANCER CELLS | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | INDUCTION | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | DEATH | - |
dc.subject.keywordPlus | BAX | - |
dc.subject.keywordAuthor | Anticancer candidate | - |
dc.subject.keywordAuthor | beta-Lapachone | - |
dc.subject.keywordAuthor | CYP inhibition | - |
dc.subject.keywordAuthor | Drug-drug interaction | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs00280-013-2230-x | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.